• Novo Holdings co-led OMass Therapeutics’ oversubscribed £230 million ($310 million) Series C financing with Bain Capital Life Sciences and Forbion.
• OMass develops small-molecule therapeutics in endocrinology and immunology.
• Proceeds will advance OMS1620 through Phase 2 clinical development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.
• Funding will also support earlier-stage programs, including initial clinical data for an SLC15A4 inhibitor targeting lupus and other immune-related diseases.
• Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences participated, alongside all existing investors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.